Literature DB >> 6117726

Ribavirin small-particle aerosol treatment of influenza.

V Knight, H W McClung, S Z Wilson, B K Waters, J M Quarles, R W Cameron, S E Greggs, J M Zerwas, R B Couch.   

Abstract

In an outbreak of influenza virus A/England/333/80(H1N1) infections in college students, 14 randomly selected patients were treated by inhalation of ribavirin small-particle aerosol through a face mask. They retained an average estimated 1.15 g of drug in 23 h of treatment given over 3 days. 17 patients served as controls. Ribavirin aerosol treatment had a therapeutic effect judged by the highly significant reduction in height and duration of fever, reduction in systemic illness, and disappearance of influenza virus from respiratory secretions. 1 additional patient with influenzal pneumonia caused by a strain of influenza virus A/Bangkok/79(H3N2) recovered promptly with ribavirin aerosol treatment.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6117726     DOI: 10.1016/s0140-6736(81)91152-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  49 in total

Review 1.  Lower airway obstruction in the PICU.

Authors:  S A Kecskes
Journal:  Indian J Pediatr       Date:  1990 Mar-Apr       Impact factor: 1.967

2.  Safety and pharmacokinetics of rimantadine small-particle aerosol.

Authors:  R L Atmar; S B Greenberg; J M Quarles; S Z Wilson; B Tyler; S Feldman; R B Couch
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Inhibition of immune functions by antiviral drugs.

Authors:  W Heagy; C Crumpacker; P A Lopez; R W Finberg
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

Review 4.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

Review 5.  Clinical pharmacokinetics of inhaled antimicrobials.

Authors:  Chris Stockmann; Jessica K Roberts; Venkata K Yellepeddi; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

6.  Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro.

Authors:  F G Hayden; A N Schlepushkin; N L Pushkarskaya
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

7.  MegaRibavirin aerosol for the treatment of influenza A virus infections in mice.

Authors:  Brian E Gilbert; Matthew T McLeay
Journal:  Antiviral Res       Date:  2008-02-04       Impact factor: 5.970

8.  Ribavirin aerosol for acute bronchiolitis.

Authors:  W Barry; F Cockburn; R Cornall; J F Price; G Sutherland; A Vardag
Journal:  Arch Dis Child       Date:  1986-06       Impact factor: 3.791

9.  Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Scott A Harper; John S Bradley; Janet A Englund; Thomas M File; Stefan Gravenstein; Frederick G Hayden; Allison J McGeer; Kathleen M Neuzil; Andrew T Pavia; Michael L Tapper; Timothy M Uyeki; Richard K Zimmerman
Journal:  Clin Infect Dis       Date:  2009-04-15       Impact factor: 9.079

10.  Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent.

Authors:  J J Kirsi; J A North; P A McKernan; B K Murray; P G Canonico; J W Huggins; P C Srivastava; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.